Navigation Links
China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
Date:8/7/2008

Shanghai, China, Aug. 7 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT), a leading Chinese firm specializing in the research, development, manufacture, marketing and distribution of probiotics dietary supplements, today announced it will host a conference call at 9:00 a.m. EDT on Friday, August 15, 2008, to discuss the Company's financial results for the first quarter ended June 30, 2008, of its fiscal 2009.

Hosting the call will be Jinan Song, Chairman and Chief Executive Officer, Raymond Li, Chief Financial Officer, and Henry Tai, Vice President of Corporate Development.

To participate in the event by telephone, please dial (888) 241-0558 five to 10 minutes prior to the start time (to allow time for registration) and reference the conference ID 58187212. International callers should dial (647) 427-3417.

A digital replay of the call will be available on Friday, August 15 at approximately 11:00 a.m. EDT through Friday, August 22 at midnight EDT. To listen to the replay, dial (800) 678-0453 and enter the conference ID number 58187212. International callers should dial (402) 220-1458 and enter the same conference ID number.

The conference call will also be webcast live over the Internet and can be accessed by all interested parties at the company's Web site, http://www.chn-biotics.com .

To monitor the live webcast, please go to this web site at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. An audio replay of the event will be archived on China-Biotics' Web site at http://www.chn-biotics.com/ for 90 days.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribu
'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. China-Biotics, Inc. Files Application for Nasdaq Listing
2. China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008
3. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results
4. China-Biotics, Inc. to Present at Chinas 3rd Annual Food Safety Technology Forum 2008
5. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2008 Results
6. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
7. China-Biotics, Inc. to Present at Two Upcoming Investor Conferences
8. China-Biotics, Inc. Completes Foundation for Its New Plant
9. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
10. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
11. China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 2BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 4Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6